31
Participants
Start Date
May 31, 2010
Primary Completion Date
December 31, 2012
Study Completion Date
August 31, 2013
Moxifloxacin (Avelox, BAY12-8039)
Single intravenous (IV) infusion of moxifloxacin administered over 60 minutes, at an initial dosage of 5 milligram per kilogram per body weight (mg/kg/BW) with dose escalation to 6 mg/kg in subjects of age 6 years (yrs) to less than or equal to (\<=) 14 years.
Moxifloxacin (Avelox, BAY12-8039)
Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 7 mg/kg/BW with dose escalation to 8 mg/kg in subjects of age 2 years to less than (\<) 6 years; dose escalation was based on evaluations of the pharmacokinetic (PK) and safety data from the subjects in a preceding cohort.
Moxifloxacin (Avelox, BAY12-8039)
Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 9 mg/kg/BW with dose escalation to 10 mg/kg in subjects of age 3 months to \< 2 years; dose escalation was based on evaluations of the PK and safety data from the subjects in a preceding cohort.
Louisville
Toledo
Cleveland
Little Rock
Salt Lake City
Orange
San Diego
New Orleans
Boston
Kansas City
Cincinnati
Lead Sponsor
Bayer
INDUSTRY